Drug response across different cancer lineages for a subset of CCLE compounds.

<p>Boxplots indicate the distribution of drug sensitivity values (based on IC50) in each cancer lineage to each cancer drug. For example, most cancer lineages are resistant to L-685458 (with IC50 around 10⁻⁵ M) except for haematopoietic cancers (IC50 from 10⁻⁵ to 10⁻⁸ M). The number of samples in a cancer lineage screened for drug response is shown under the corresponding boxplot. Compounds denoted in blue text exhibited a broad range of responses in multiple cancer lineages and were selected for analysis in this study, whereas compounds denoted in red text are examples of compounds excluded from analysis. Cancer lineage abbreviations – <b>AU</b>: autonomic; <b>BO</b>: bone; <b>BR</b>: breast; <b>CN</b>: central nervous system; <b>EN</b>: endometrial; <b>HE</b>: haematopoietic/lymphoid; <b>KI</b>: kidney; <b>LA</b>: large intestine; <b>LI</b>: liver; <b>LU</b>: lung; <b>OE</b>: oesophagus; <b>OV</b>: ovary; <b>PA</b>: pancreas; <b>PL</b>: pleura; <b>SK</b>: skin; <b>SO</b>: soft tissue; <b>ST</b>: stomach; <b>TH</b>: thyroid; <b>UP</b>: upper digestive; <b>UR</b>: urinary